Form 4 for TNDM TANDEM DIABETES CARE INC
Accepted 2025-05-19 00:00:00 ET · period of report 2025-05-15 · accession 0001438133-25-000085 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-05-19 | 2025-05-15 | TNDM | Sheridan John F | Pres, CEO, Dir | M - OptEx | $3.83 | +32.4K | 81.2K | +67% | +$124.2K |
| DM | 2025-05-19 | 2025-05-15 | TNDM | Sheridan John F | Pres, CEO, Dir | F - Tax | $22.70 | -16.5K | 96.3K | -15% | -$373.9K |
| D | 2025-05-19 | 2025-05-15 | TNDM | Sheridan John F | Pres, CEO, Dir | A - Grant | $15.64 | +1,359 | 80.4K | +2% | +$21.3K |
| DM | 2025-05-19 | 2025-05-15 | TNDM | Sheridan John F | Pres, CEO, Dir | M - OptEx | $0.00 | -32.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-15 | M | A | 23,929 | $0.00 | 108,479 | D | — | — | |
| 2 | Common | Common Stock | 2025-05-15 | F | D | 2,779 | $22.70 | 84,550 | D | — | — | |
| 3 | Common | Common Stock | 2025-05-15 | M | A | 5,472 | $22.70 | 87,329 | D | — | — | |
| 4 | Common | Common Stock | 2025-05-15 | F | D | 1,136 | $22.70 | 81,857 | D | — | — | |
| 5 | Common | Common Stock | 2025-05-15 | A | A | 1,359 | $15.64 | 80,368 | D | — | — | (F1) The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c). |
| 6 | Common | Common Stock | 2025-05-15 | F | D | 403 | $22.70 | 80,757 | D | — | — | |
| 7 | Common | Common Stock | 2025-05-15 | M | A | 2,236 | $0.00 | 82,993 | D | — | — | |
| 8 | Common | Common Stock | 2025-05-15 | M | A | 792 | $0.00 | 81,160 | D | — | — | |
| 9 | Common | Common Stock | 2025-05-15 | F | D | 12,152 | $22.70 | 96,327 | D | — | — | |
| 10 | Derivative | Restricted Stock Unit | 2025-05-15 | M | D | 5,472 | $0.00 | 21,886 | D | — · — to — | 5,472 Common Stock | (F8) Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). (F9) Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. (F10) RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. |
| 11 | Derivative | Restricted Stock Unit | 2025-05-15 | M | D | 23,929 | $0.00 | 47,858 | D | — · — to — | 23,929 Common Stock | (F11) Awarded on May 23, 2024 pursuant to the 2023 Plan. (F9) Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. (F12) RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. |
| 12 | Derivative | Restricted Stock Unit | 2025-05-15 | M | D | 792 | $0.00 | 0 | D | — · — to — | 792 Common Stock | (F3) Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). (F4) Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. (F5) RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. |
| 13 | Derivative | Restricted Stock Unit | 2025-05-15 | M | D | 2,236 | $0.00 | 0 | D | — · — to — | 2,236 Common Stock | (F6) Awarded on May 25, 2022 pursuant to the 2013 Plan. (F4) Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. (F7) RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. |